Esomeprazole Strontium Salt, Process For Its Preparation and Pharmaceutical Compositions Containing Same
A strontium salt of esomeprazole is provided. A process for preparing a strontium salt of esomeprazole is also provided comprising reacting esomeprazole free base or a sodium, potassium or lithium salt of esomeprazole with a strontium source in one or more solvents.
1 . A process for preparing a strontium salt of esomeprazole, the process comprising reacting esomeprazole free base or a sodium, potassium or lithium salt of esomeprazole with a strontium source in one or more solvents.
2 - 5 . (canceled)
6 . The process of claim 1 , wherein the strontium source is selected from the group consisting of an inorganic acid salt of strontium, organic acid salt of strontium and mixtures thereof.
7 . The process of claim 1 , wherein the strontium source is selected from the group consisting of strontium chloride, strontium chloride hexahydrate, strontium isopropoxide, strontium nitrate, strontium bromide, strontium sulfate, strontium carbonate, strontium acetate, strontium oxalate, strontium tartrate, strontium succinate and mixtures thereof.
8 . The process of claim 1 , wherein the amount of the strontium source is from about 1 to about 5 molar equivalents per molar equivalent of the esomeprazole free base or the sodium, potassium or lithium salt of esomeprazole.
9 . The process of claim 1 , wherein the solvent is selected from the group consisting of water, C 1 -C 10 alcohol, C 1 -C 10 ketone, C 1 -C 10 cyclic ether, chlorinated hydrocarbon, nitrile, dipolar aprotic solvent and mixtures thereof.
10 - 13 . (canceled)
14 . The process of claim 1 , further comprising precipitating the strontium salt of esomeprazole and recovering the strontium salt of esomeprazole.
15 . The process of claim 1 , comprising reacting a first solvent solution comprising esomeprazole free base or a sodium, potassium or lithium salt of esomeprazole and a first solvent with a second solvent solution comprising a strontium source and a second solvent.
16 . (canceled)
17 . The process of claim 15 , wherein the first and second solvent are water or an alcohol.
18 . The process of claim 15 , wherein the first and second solvent are water or isopropanol.
19 . (canceled)
20 . The process of claim 15 , further comprising precipitating the strontium salt of esomeprazole and recovering the strontium salt of esomeprazole.
21 . (canceled)
22 . The process of claim 20 , wherein the step of precipitating the strontium salt of esomeprazole comprises adding an anti solvent to the reaction solution.
23 - 26 . (canceled)
27 . The process of claim 1 , wherein the strontium salt of esomeprazole has a purity of greater than or equal to about 95%.
28 - 29 . (canceled)
30 . The process of claim 1 , wherein the strontium salt of esomeprazole has an enantiomeric excess of greater than or equal to about 95%.
31 - 33 . (canceled)
34 . A strontium salt of esomeprazole or a derivative thereof.
35 . The strontium salt of esomeprazole of claim 34 , which is substantially.
36 . (canceled)
37 . The strontium salt of esomeprazole of claim 35 , having a purity of greater than or equal to about 98%.
38 . (canceled)
39 . The strontium salt of esomeprazole of claim 34 , having an enantiomeric excess of greater than or equal to about 95%.
40 - 41 . (canceled)
42 . A pharmaceutical composition comprising a therapeutically effective amount of the strontium salt of esomeprazole of claim 34 .
43 - 46 . (canceled)
47 . The pharmaceutical composition of claim 42 , wherein the strontium salt of esomeprazole is a micronized strontium salt of esomeprazole having a particle size of less than about 15 microns.
48 - 50 . (canceled)
51 . A method for treating a gastric acid related condition, the method comprising administering to a subject in need of treatment thereof a therapeutically effective amount of a strontium salt of esomeprazole of claim 34 .
52 . (canceled)